Bonifacio Consulting Services03.10.16
Bonifacio Consulting Services would like to share the announcement of the transaction between BD (Becton, Dickinson and Company), a global medical technology company, and Apax Partners, a global private equity firm. BD announced a definitive agreement to sell 50.1 percent of its Respiratory Solutions business to funds advised by Apax Partners, and form a joint venture that will operate as a new, independent company. BD will retain 49.9 percent of the company as a significant but non-controlling minority owner.
BCS was part of the advisory team supporting the operational due diligence on the BD Respiratory Solutions business for Apax Partners, enabling Apax to complete the agreement with BD. “The deep domain expertise of our team at BCS, working alongside APAX and its other Diligence team members allowed us to provide actionable insight into this multi-plant global operation, while also providing specific areas for future value capture as the business moves forward as a new standalone entity” added Mark Bonifacio , President BCS.
The new company will include all business lines within BD’s Respiratory Solutions business including Ventilation, Respiratory Diagnostics, Vital Signs and AirLife. The transaction values the entire business today at nearly $500 million and has an estimated annual revenue of approximately $900 million.
The Bonifacio Consulting team has decades of hands on global medical device manufacturing operational experience and delivers an in-depth review and analysis of current manufacturing operations while providing a value capture roadmap for future operational activities to support future growth.
BCS was part of the advisory team supporting the operational due diligence on the BD Respiratory Solutions business for Apax Partners, enabling Apax to complete the agreement with BD. “The deep domain expertise of our team at BCS, working alongside APAX and its other Diligence team members allowed us to provide actionable insight into this multi-plant global operation, while also providing specific areas for future value capture as the business moves forward as a new standalone entity” added Mark Bonifacio , President BCS.
The new company will include all business lines within BD’s Respiratory Solutions business including Ventilation, Respiratory Diagnostics, Vital Signs and AirLife. The transaction values the entire business today at nearly $500 million and has an estimated annual revenue of approximately $900 million.
The Bonifacio Consulting team has decades of hands on global medical device manufacturing operational experience and delivers an in-depth review and analysis of current manufacturing operations while providing a value capture roadmap for future operational activities to support future growth.